Artículos por temáticas

BACE Inhibitor Clinical Trials for Alzheimer's Disease

Watkins EA, Vassar R.

J Alzheimers Dis. 2024;101(s1):S41-S52. doi: 10.3233/JAD-231258.

The impact of chelating compounds on Cu(2+), Fe(2+)/(3+), and Zn(2+) ions in Alzheimer's disease treatment

Mazur T, Malik M, Bieńko DC.

J Inorg Biochem. 2024 Aug;257:112601. doi: 10.1016/j.jinorgbio.2024.112601. Epub 2024 May 9.

Serotonin in depression and Alzheimer's disease: Focus on SSRI's beneficial effects

Tahiri J, Mian M, Aftan F, Habbal S, Salehi F, Reddy PH, Reddy AP.

Ageing Res Rev. 2024 Nov;101:102537. doi: 10.1016/j.arr.2024.102537. Epub 2024 Oct 9.

Drugs targeting APOE4 that regulate beta-amyloid aggregation in the brain: Therapeutic potential for Alzheimer's disease

Poblano J, Castillo-Tobías I, Berlanga L, Tamayo-Ordoñez MC, Del Carmen Rodríguez-Salazar M, Silva-Belmares SY, Aguayo-Morales H, Cobos-Puc LE.

Basic Clin Pharmacol Toxicol. 2024 Sep;135(3):237-249. doi: 10.1111/bcpt.14055. Epub 2024 Jul 17.

GSK3: A potential target and pending issues for treatment of Alzheimer's disease

Zhao J, Wei M, Guo M, Wang M, Niu H, Xu T, Zhou Y.

CNS Neurosci Ther. 2024 Jul;30(7):e14818. doi: 10.1111/cns.14818.

Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease

Meur S, Mukherjee S, Roy S, Karati D.

Mol Neurobiol. 2024 Dec;61(12):10941-10955. doi: 10.1007/s12035-024-04257-7. Epub 2024 May 30.

Impact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach

Sharma V, Chander Sharma P, Reang J, Yadav V, Kumar Tonk R, Majeed J, Sharma K.

Bioorg Chem. 2024 Jun;147:107378. doi: 10.1016/j.bioorg.2024.107378. Epub 2024 Apr 17.

Caring for Persons with Alzheimer's Disease during a Pandemic: An Integrative Literature Review

Kokoszka L, Pariseault C, Pariseault CA, Hunter D.

Home Healthc Now. 2024 Sep-Oct 01;42(5):267-276. doi: 10.1097/NHH.0000000000001288. Epub 2024 Sep 9.

Surface engineered nano architectonics: An evolving paradigm for tackling Alzheimer's disease

Negi M, Amulya E, Phatale V, Abraham N, Hedaoo A, Srinivasarao DA, Srivastava S.

Life Sci. 2024 Dec 1;358:123155. doi: 10.1016/j.lfs.2024.123155. Epub 2024 Oct 19.

Exploring the Therapeutic Potential of BBB-Penetrating Phytochemicals With p38 MAPK Modulatory Activity in Addressing Oxidative Stress-Induced Neurodegenerative Disorders, With a Focus on Alzheimer's Disease

Hosseini A, Sheibani M, Valipour M.

Phytother Res. 2024 Dec;38(12):5598-5625. doi: 10.1002/ptr.8329. Epub 2024 Sep 19.

Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's

Song T, Wang Y, Silverglate BD, Grossberg GT.

Expert Opin Drug Metab Toxicol. 2024 Jun;20(6):411-417. doi: 10.1080/17425255.2024.2357637. Epub 2024 May 20.

The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors

Moss DE, Perez RG.

J Alzheimers Dis. 2024 Dec;102(3):617-626. doi: 10.1177/13872877241289602. Epub 2024 Nov 12.

Opportunities and challenges for the development of M(1) muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits

Nguyen HTM, van der Westhuizen ET, Langmead CJ, Tobin AB, Sexton PM, Christopoulos A, Valant C.

Br J Pharmacol. 2024 Jul;181(14):2114-2142. doi: 10.1111/bph.15982. Epub 2022 Dec 4.

Caspases in Alzheimer's Disease: Mechanism of Activation, Role, and Potential Treatment

Wójcik P, Jastrzębski MK, Zięba A, Matosiuk D, Kaczor AA.

Mol Neurobiol. 2024 Jul;61(7):4834-4853. doi: 10.1007/s12035-023-03847-1. Epub 2023 Dec 23.

Exosomes in multiple sclerosis and Alzheimer's disease - Adversary and ally

Tang N.

Biomed J. 2024 Oct;47(5):100665. doi: 10.1016/j.bj.2023.100665. Epub 2023 Sep 29.